NanoViricides’s Broad-Spectrum Antiviral Drug Candidate for the Treatment of COVID-19 Infections was Well Tolerated in GLP and non-GLP Animal Safety Studies
SHELTON, CT / ACCESSWIRE / February 8, 2021 / NanoViricides, Inc. (NYSE American: NNVC) (the…